SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 630.99+0.5%10:18 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (3417)12/13/2021 3:32:18 PM
From: CuttingEdge Bio  Read Replies (1) of 3557
 
Not MERS but SARS. A shared epitope on the SARS spike that is highly conserved in both SARS and SARS Cov2 coronaviruses. It is outside the receptor binding motif. RBM and RBD tend to have higher mutation rates naturally. VIR has no cross reactivity to MERS.
But it is unusual that this omicron popped up with such an evolutionary leap like this. I don't fully buy that it was naturally occurring.
There may be some restriction on mutation at the VIR site because of the necessary glycosylation structure and protein folding that would be impacted.
But there are already Omicron sublineages developing in multiple countries. And REGN study in Science already showed that no matter how conserved the site, when you passage in vitro all monotherapies are quickly adapted and escaped. So if sotrovimab gets used more, this may be escaped soon too.
The saving grace would only be if those variants that form in vitro are not actually stable in the wild and cannot become dominant.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News